Providence Business News

Rubius Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference

Retrieved on: 
Monday, September 19, 2022
Rubius, Investor, Twitter, Red Cell, Providence Business News, Nasdaq, U.S. Securities and Exchange Commission, News, LinkedIn, Company, Private Securities Litigation Reform Act, Therapy, The Boston Globe, Cancer, Degenerative disease, Conference, GLOBE, SEC, El Rubius, RED, Security (finance), Facebook

A live audio webcast will be available within the Investors & Media section of the Rubius Therapeutics website.

Key Points: 
  • A live audio webcast will be available within the Investors & Media section of the Rubius Therapeutics website.
  • An archived replay will be accessible for 90 days following the event.
  • Rubius Therapeutics is a biopharmaceutical company that is developing an entirely new class of cellular medicines called Red Cell Therapeutics for the treatment of cancer and autoimmune diseases.
  • We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made.

Michael Puorro Joins Embrace Home Loans' Basking Ridge, NJ Office

Retrieved on: 
Friday, September 16, 2022
Embrace, Fannie Mae, Embrace Home Loans, Fortune, Providence Business News, News, Basking Ridge, New Jersey, Most, Industry, Government, The Last Best Place, District, Scotsman Guide, Freddie Mac, Ridge, FHA, Real estate

MIDDLETOWN, R.I., Sept. 16, 2022 /PRNewswire/ -- Embrace Home Loans, a top-ranked national mortgage lender, announced that leading mortgage originator Michael Puorro has joined its Basking Ridge, New Jersey branch as producing sales manager. Also joining Embrace from Caliber are: Matt Rossine, junior loan officer, Eric Hantson, business development associate and Chantelle Perkins, business development associate. 

Key Points: 
  • MIDDLETOWN, R.I., Sept. 16, 2022 /PRNewswire/ -- Embrace Home Loans , a top-ranked national mortgage lender, announced that leading mortgage originator Michael Puorro has joined its Basking Ridge, New Jersey branch as producing sales manager.
  • Mortgage Executive magazine ranked Puorro among the top 1% of mortgage originators in 2019, 2020 and 2021.
  • "Michael is a fantastic addition to the Embrace team," said Steve Adamo, president, national retail production.
  • "We're thrilled to have Michael join our office," said Brian Woltman, Basking Ridge branch manager.

Rubius Therapeutics Announces Strategic Update

Retrieved on: 
Tuesday, September 13, 2022
Rubius, Investor, RCC, Solar cycle 12, Corporation, Anal cancer, Twitter, Autoimmunity, Red Cell, Sale, EDT, NSCLC, Providence Business News, Nivolumab, Nasdaq, U.S. Securities and Exchange Commission, News, Colorectal cancer, LinkedIn, Company, Carcinoma, Review, Private Securities Litigation Reform Act, Melanoma, Therapy, Red blood cell, The Boston Globe, Patient, Cancer, AES, Protein, Webcast, Cell, Head, Degenerative disease, Renal cell carcinoma, Research, Large-cell lung carcinoma, GLOBE, SEC, RED, El Rubius, Pembrolizumab, Spleen, HIV disease progression rates, Security (finance), Fine chemical, Pharmaceutical industry, Vaccine, Facebook

CAMBRIDGE, Mass., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a biopharmaceutical company that is developing an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced plans to restructure the Company and align resources to advance its next generation red blood cell-based cell conjugation platform.

Key Points: 
  • With more than 80 patients dosed across three clinical trials to date, Rubius Therapeutics has demonstrated that engineered red blood cells can be manufactured at scale, safely administered and activate a patients immune system, resulting in clinical benefit in certain cancer patients, including evidence of tumor shrinkage and prolonged stable disease in PD-(L)-1 refractory solid tumors, said Pablo J. Cagnoni, M.D., president and chief executive officer of Rubius Therapeutics.
  • Based on these early findings, we firmly believe in the potential of Red Cell Therapeutics for the treatment of cancer and autoimmunity.
  • An audio webcast will be available on the Events and Presentations page within the Investors and Media section of the Rubius Therapeutics website and can be directly accessed here .
  • Rubius Therapeutics is a biopharmaceutical company that is developing an entirely new class of cellular medicines called Red Cell Therapeutics for the treatment of cancer and autoimmune diseases.

Rubius Therapeutics to Provide Strategic Update

Retrieved on: 
Monday, September 12, 2022
Rubius, Investor, Twitter, Red Cell, EDT, Providence Business News, News, LinkedIn, Company, Therapy, The Boston Globe, Cancer, Nasdaq, Degenerative disease, GLOBE, RED, El Rubius, Webcast, Pharmaceutical industry, Facebook

CAMBRIDGE, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics for the treatment of cancer and autoimmune diseases, today announced that the Company plans to provide a strategic update and host an investor teleconference and webcast on Tuesday, September 13, 2022, at 7:30 a.m. EDT.

Key Points: 
  • CAMBRIDGE, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics for the treatment of cancer and autoimmune diseases, today announced that the Company plans to provide a strategic update and host an investor teleconference and webcast on Tuesday, September 13, 2022, at 7:30 a.m. EDT.
  • An audio webcast will be available on the Events and Presentations page within the Investors and Media section of the Rubius Therapeutics website and can be directly accessed here .
  • Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics.
  • Rubius initial focus is to advance RCT product candidates for the treatment of cancer and autoimmune diseases by leveraging two distinct therapeutic modalities potent cell-cell interaction and tolerance induction.

Bragar Eagel & Squire, P.C. Is Investigating Singularity, Phathom, EyePoint, and Olo and Encourages Investors to Contact the Firm

Retrieved on: 
Wednesday, September 7, 2022
Inflammation, Partnership, Mining, NYSE, Technology, OLO, Run, NASDAQ, Sale, Hindenburg Research, Providence Business News, Charles Ponzi, Restaurant, District, GLOBE, Miner, Company, FDA, Singularity, News, KOI, Hindenburg, Pharmaceutical industry, Cryptocurrency, Audit, Subway, P.C

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • On this news, Singularitys stock price fell $1.95 per share, or 28.89%, to close at $4.80 per share on May 5, 2022.
  • For more information on the Olo investigation go to: https://bespc.com/cases/OLO
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Embrace Home Loans Sponsoring Stars and Stripes Veteran Golf Tournament on September 9, 2022

Retrieved on: 
Tuesday, August 16, 2022
Association, Fortune, District, Aikman, Veteran, Star, The Last Best Place, Family, Program, News, Providence Business News, Real estate, Embrace Home Loans, Most, Golf, United States Navy Veterans Association, Organization, Management, Embrace

MIDDLETOWN, R.I., Aug. 16, 2022 /PRNewswire/ -- Embrace Home Loans, a top-ranked lender in the mortgage industry, announced that their Fairfax, Virginia office will sponsor the Stars and Stripes Golf Tournament, which will be hosted by the Veterans Association of Real Estate Professionals (VAREP) of Northern Virginia. The tournament will be held on Friday, September 9, 2022, in Quantico, VA.

Key Points: 
  • Embrace Senior Loan Officer David Aikman, Fairfax, Virginia, is the vice president of the Northern Virginia chapter of VAREP and is coordinating the golf tournament.
  • He will also be sponsoring some of his veteran clients who are interested in playing in the tournament to show his gratitude for their service.
  • "The Stars and Stripes Veteran Charity Golf tournament provides a fun day of golf while raising money to aid many local veterans in need.
  • As with previous Stars and Stripes Golf Tournaments, there will be prizes for hole-in-one, closest to the pin, and longest drive.

Bragar Eagel & Squire, P.C. Is Investigating NIO, Discover, MINISO, and Phathom and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, August 16, 2022
Transfer, Discover Financial, FDA, U.S. Securities and Exchange Commission, Providence Business News, NYSE, GLOBE, Electronic Fund Transfer Act, NIO, ADS, Holding, American depositary receipt, Consumer, DFS, MNSO, Company, Holding Foreign Companies Accountable Act, CFPB, Hong Kong Stock Exchange, NASDAQ, News, Solution, Annual report, IPO, ADR, Online gambling, Security (finance), Renewable energy, Audit, Bank, P.C, Discover

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • On this news, NIO's American depositary receipt ("ADR") price fell $2.75 per ADR, or 15.17%, to close at $15.38 per ADR on May 5, 2022.
  • For more information on the Phathom investigation go to: https://bespc.com/cases/PHAT
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Bragar Eagel & Squire, P.C. Is Investigating Phathom, TuSimple, Mercury Systems, and Cassava and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, August 11, 2022
FDA, Experiment, Travel, Federal Motor Carrier Safety Administration, Providence Business News, Mercury Systems, GLOBE, Mercury, Compliance, PLOS One, Cassava, Company, Acquisition, Glass house, MRCY, Safety, NASDAQ, Physical optics, News, Journal, The Wall Street Journal, The New York Times, Pharmaceutical industry, Audit, Renewable energy, P.C

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • Finally, the Company announced that [t]hese additional activities will result in a delay of the planned VOQUEZNA DUAL PAK and VOQUEZNA TRIPLE PAK product launches.
  • For more information on the Cassava investigation go to: https://bespc.com/cases/SAVA
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

ROSEN, A LEADING LAW FIRM, Encourages Phathom Pharmaceuticals, Inc. Investors with Losses Exceeding $100K to Inquire About Securities Class Action Investigation – PHAT

Retrieved on: 
Thursday, August 11, 2022
Titan, FDA, Providence Business News, GLOBE, TO, Facebook, Advertising, Twitter, I-Space (Chinese company), WHY, NASDAQ, News, LinkedIn, Security (finance)

The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

Key Points: 
  • The Rosen Law Firm is preparing a class action seeking recovery of investor losses.
  • WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=7943 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

ROSEN, A LEADING LAW FIRM, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – PHAT

Retrieved on: 
Saturday, August 6, 2022
Titan, FDA, Providence Business News, GLOBE, TO, Facebook, Advertising, Twitter, I-Space (Chinese company), WHY, NASDAQ, News, LinkedIn, Security (finance)

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=7943 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=7943 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.